Clinical Trial Update: Immunogenicity and Persistence of GlaxoSmithKline (GSK) Biologicals' Havrix® in Healthy Adult Subjects Vaccinated at Infancy Under the Hepatitis A Universal Mass Vaccination (UMV) Program in Israel [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating the immunogenicity and persistence of Havrix in healthy adults vaccinated in infancy under Israel's universal vaccination pr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis A

Drugs mentioned

• Havrix (hepatitis A vaccine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis A | Phase 4 | Status: WITHDRAWN